factual
Evergreening And Product Hopping Block Generics
Within Hatch-Waxman, companies practice evergreening and product hopping—making a minor modification to a drug's delivery, dosage, or form right as the patent expires, obtaining a new patent on the trivially changed version, and then withdrawing the old version so generics of the original cannot be substituted.
factualpending
Speaker
Robin FeldmanEvidence Quote
“you try to make a minor modification to the drug's delivery or dosage or something else related to the system and then get a new patent on this new version”
Created: 6/13/2026, 12:11:23 AM
Your notes
Loading notes...